Diseases impacted by metabolic dysregulation, such as liver-, kidney-, and heart diseases, share a common trait—significantly upregulated fibroblast activity. This increased fibrotic burden, called fibrosis, is a leading cause of death worldwide.
Fibrosis-specific biomarkers can help us understand fibroblast activity and, more importantly, how to regulate it, which can be the key advance our understanding of metabolic diseases and lead to more targeted and successful treatments.
Search and find publications that we have published.
Please don't hesitate to contact us if you have any questions or other inquiries.
